BRIOLI, ANNAMARIA
BRIOLI, ANNAMARIA
DIPARTIMENTO DI MEDICINA SPECIALISTICA, DIAGNOSTICA E SPERIMENTALE (attivo dal 28/10/2011 al 31/12/2022)
Pomalidomide combinations are a safe and effective option after daratumumab failure
2023 Annamaria Brioli; Laura Gengenbach; Katia Mancuso; Mascha Binder; Thomas Ernst; Florian H. Heidel; Thomas Stauch; Elena Zamagni; Inken Hilgendorf; Andreas Hochhaus; Monika Engelhardt; Marie von Lilienfeld-Toal
Melphalan 200 mg/m2 does not increase toxicity and improves survival in comparison to reduced doses of melphalan in multiple myeloma patients
2021 Brioli A.; vom Hofe F.; Rucci P.; Ernst T.; Yomade O.; Hilgendorf I.; Scholl S.; Sayer H.; Mugge L.-O.; Hochhaus A.; von Lilienfeld-Toal M.
Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma
2016 Pantani, L; Brioli, A; Tacchetti, P; Zannetti, B A; Mancuso, K; Rocchi, Serena; Martello, M; Rizzello, I; Terragna, C; Zamagni, E; Cavo, M
Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens
2016 Tacchetti, Paola; Cavo, Michele; Rocchi, Serena; Pezzi, Annalisa; Pantani, Lucia; Brioli, Annamaria; Testoni, Nicoletta; Terragna, Carolina; Zannetti, BEATRICE ANNA; Mancuso, Katia; Marzocchi, Giulia; Borsi, Enrica; Martello, Marina; Rizzello, Ilaria; Zamagni, Elena
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD)
2016 Terragna, Carolina; Remondini, Daniel; Martello, Marina; Zamagni, Elena; Pantani, Lucia; Patriarca, Francesca; Pezzi, Annalisa; Levi, Giuseppe; Offidani, Massimo; Proserpio, Ilaria; De Sabbata, Giovanni; Tacchetti, Paola; Cangialosi, Clotilde; Ciambelli, Fabrizio; Viganò, Clara Virginia; Dico, Flores Angela; Santacroce, Barbara; Borsi, Enrica; Brioli, Annamaria; Marzocchi, Giulia; Castellani, Gastone; Martinelli, Giovanni; Palumbo, Antonio; Cavo, Michele
Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment
2015 Zannetti, Beatrice Anna; Zamagni, Elena; Santostefano, Marisa; De Sanctis, Lucia Barbara; Tacchetti, Paola; Mancini, Elena; Pantani, Lucia; Brioli, Annamaria; Rizzo, Raffaella; Mancuso, Katia; Rocchi, Serena; Pezzi, Annalisa; Borsi, Enrica; Terragna, Carolina; Marzocchi, Giulia; Santoro, Antonio; Cavo, Michele
Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma
2015 Cavo, M; Pantani, L; Pezzi, A; Petrucci, M T; Patriarca, F; Di Raimondo, F; Marzocchi, G; Galli, M; Montefusco, V; Zamagni, E; Gamberi, B; Tacchetti, P; Brioli, A; Palumbo, A; Sonneveld, P
PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma
2015 Zamagni, Elena; Nanni, Cristina; Mancuso, Katia; Tacchetti, Paola; Pezzi, Annalisa; Pantani, Lucia; Zannetti, Beatrice; Rambaldi, Ilaria; Brioli, Annamaria; Rocchi, Serena; Terragna, Carolina; Martello, Marina; Marzocchi, Giulia; Borsi, Enrica; Rizzello, Ilaria; Fanti, Stefano; Cavo, Michele
Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation
2015 Brioli, A; Perrone, G; Patriarca, F; Pezzi, A; Nobile, F; Ballerini, F; Motta, M R; Ronconi, S; Tacchetti, P; Catalano, L; Zannetti, B A; Rizzi, S; Volpe, S; Zamagni, E; Liberati, A M; Mancuso, K; Boccadoro, M; Davies, F E; Morgan, G J; Palumbo, A; Cavo, M
Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma
2015 Borsi, Enrica; Terragna, Carolina; Brioli, Annamaria; Tacchetti, Paola; Martello, Marina; Cavo, Michele
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes
2014 Lucia Pantani;Elena Zamagni;Beatrice Anna Zannetti;Annalisa Pezzi;Paola Tacchetti;Annamaria Brioli;Katia Mancuso;Giulia Perrone;Serena Rocchi;Patrizia Tosi;Michele Cavo
HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment
2014 Enrica Borsi;Giulia Perrone;Carolina Terragna;Marina Martello;Elena Zamagni;Paola Tacchetti;Lucia Pantani;Annamaria Brioli;Angela Flores Dico;Beatrice Anna Zannetti;Serena Rocchi;Michele Cavo
Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms.
2014 Walker BA;Wardell CP;Melchor L;Brioli A;Johnson DC;Kaiser MF;Mirabella F;Lopez-Corral L;Humphray S;Murray L;Ross M;Bentley D;Gutiérrez NC;Garcia-Sanz R;San Miguel J;Davies FE;Gonzalez D;Morgan GJ
Maintenance therapy in newly diagnosed multiple myeloma: current recommendations.
2014 Brioli, A; Tacchetti, P; Zamagni, E; Cavo, M
Peripheral neuropathy induced by subcutaneous bortezomib-based induction therapy for newly diagnosed multiple myeloma.
2014 Brioli, A; Zannetti, Ba; Zamagni, E; Tacchetti, P; Pantani, L; Mancuso, K; Pezzi, A; Rocchi, Serena; Cavo, M
Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome.
2014 Brioli A;Giles H;Pawlyn C;Campbell JP;Kaiser MF;Melchor L;Jackson GH;Gregory WM;Owen RG;Child JA;Davies FE;Cavo M;Drayson MT;Morgan GJ
Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma.
2014 Melchor L;Brioli A;Wardell CP;Murison A;Potter NE;Kaiser MF;Fryer RA;Johnson DC;Begum DB;Hulkki Wilson S;Vijayaraghavan G;Titley I;Cavo M;Davies FE;Walker BA;Morgan GJ
The impact of intra-clonal heterogeneity on the treatment of multiple myeloma.
2014 Brioli A;Melchor L;Cavo M;Morgan GJ
The impact of long-term lenalidomide exposure on the cellular composition of bone marrow.
2014 Brioli A;Melchor L;Titley I;Vijayaraghavan G;Stephens C;Zeisig A;Pawlyn C;Cavo M;Morilla R;Davies FE;Morgan GJ
The utility of newer imaging techniques as predictors of clinical outcomes in multiple myeloma.
2014 Brioli, A; Morgan, Gj; Durie, B; Zamagni, E
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| Pomalidomide combinations are a safe and effective option after daratumumab failure | Annamaria Brioli; Laura Gengenbach; Katia Mancuso; Mascha Binder; Thomas Ernst; Florian H. Heidel...; Thomas Stauch; Elena Zamagni; Inken Hilgendorf; Andreas Hochhaus; Monika Engelhardt; Marie von Lilienfeld-Toal | 2023-01-01 | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | - | 1.01 Articolo in rivista | Brioli_2023.pdf; 432_2023_4637_MOESM1_ESM.pdf |
| Melphalan 200 mg/m2 does not increase toxicity and improves survival in comparison to reduced doses of melphalan in multiple myeloma patients | Brioli A.; vom Hofe F.; Rucci P.; Ernst T.; Yomade O.; Hilgendorf I.; Scholl S.; Sayer H.; Mugge ...L.-O.; Hochhaus A.; von Lilienfeld-Toal M. | 2021-01-01 | BONE MARROW TRANSPLANTATION | - | 1.01 Articolo in rivista | - |
| Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma | Pantani, L; Brioli, A; Tacchetti, P; Zannetti, B A; Mancuso, K; Rocchi, Serena; Martello, M; Rizz...ello, I; Terragna, C; Zamagni, E; Cavo, M | 2016-01-01 | EXPERT REVIEW OF HEMATOLOGY | - | 1.01 Articolo in rivista | pantaniexpert.pdf |
| Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens | Tacchetti, Paola; Cavo, Michele; Rocchi, Serena; Pezzi, Annalisa; Pantani, Lucia; Brioli, Annamar...ia; Testoni, Nicoletta; Terragna, Carolina; Zannetti, BEATRICE ANNA; Mancuso, Katia; Marzocchi, Giulia; Borsi, Enrica; Martello, Marina; Rizzello, Ilaria; Zamagni, Elena | 2016-01-01 | LEUKEMIA & LYMPHOMA | - | 1.01 Articolo in rivista | - |
| The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD) | Terragna, Carolina; Remondini, Daniel; Martello, Marina; Zamagni, Elena; Pantani, Lucia; Patriarc...a, Francesca; Pezzi, Annalisa; Levi, Giuseppe; Offidani, Massimo; Proserpio, Ilaria; De Sabbata, Giovanni; Tacchetti, Paola; Cangialosi, Clotilde; Ciambelli, Fabrizio; Viganò, Clara Virginia; Dico, Flores Angela; Santacroce, Barbara; Borsi, Enrica; Brioli, Annamaria; Marzocchi, Giulia; Castellani, Gastone; Martinelli, Giovanni; Palumbo, Antonio; Cavo, Michele | 2016-01-01 | ONCOTARGET | - | 1.01 Articolo in rivista | - |
| Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment | Zannetti, Beatrice Anna; Zamagni, Elena; Santostefano, Marisa; De Sanctis, Lucia Barbara; Tacchet...ti, Paola; Mancini, Elena; Pantani, Lucia; Brioli, Annamaria; Rizzo, Raffaella; Mancuso, Katia; Rocchi, Serena; Pezzi, Annalisa; Borsi, Enrica; Terragna, Carolina; Marzocchi, Giulia; Santoro, Antonio; Cavo, Michele | 2015-01-01 | AMERICAN JOURNAL OF HEMATOLOGY | - | 1.01 Articolo in rivista | - |
| Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma | Cavo, M; Pantani, L; Pezzi, A; Petrucci, M T; Patriarca, F; Di Raimondo, F; Marzocchi, G; Galli, ...M; Montefusco, V; Zamagni, E; Gamberi, B; Tacchetti, P; Brioli, A; Palumbo, A; Sonneveld, P | 2015-01-01 | LEUKEMIA | - | 1.01 Articolo in rivista | - |
| PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma | Zamagni, Elena; Nanni, Cristina; Mancuso, Katia; Tacchetti, Paola; Pezzi, Annalisa; Pantani, Luci...a; Zannetti, Beatrice; Rambaldi, Ilaria; Brioli, Annamaria; Rocchi, Serena; Terragna, Carolina; Martello, Marina; Marzocchi, Giulia; Borsi, Enrica; Rizzello, Ilaria; Fanti, Stefano; Cavo, Michele | 2015-01-01 | CLINICAL CANCER RESEARCH | - | 1.01 Articolo in rivista | - |
| Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation | Brioli, A; Perrone, G; Patriarca, F; Pezzi, A; Nobile, F; Ballerini, F; Motta, M R; Ronconi, S; T...acchetti, P; Catalano, L; Zannetti, B A; Rizzi, S; Volpe, S; Zamagni, E; Liberati, A M; Mancuso, K; Boccadoro, M; Davies, F E; Morgan, G J; Palumbo, A; Cavo, M | 2015-01-01 | BONE MARROW TRANSPLANTATION | - | 1.01 Articolo in rivista | - |
| Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma | Borsi, Enrica; Terragna, Carolina; Brioli, Annamaria; Tacchetti, Paola; Martello, Marina; Cavo, M...ichele | 2015-01-01 | TRANSLATIONAL RESEARCH | - | 1.01 Articolo in rivista | - |
| Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes | Lucia Pantani;Elena Zamagni;Beatrice Anna Zannetti;Annalisa Pezzi;Paola Tacchetti;Annamaria Briol...i;Katia Mancuso;Giulia Perrone;Serena Rocchi;Patrizia Tosi;Michele Cavo | 2014-01-01 | ANNALS OF HEMATOLOGY | - | 1.01 Articolo in rivista | - |
| HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment | Enrica Borsi;Giulia Perrone;Carolina Terragna;Marina Martello;Elena Zamagni;Paola Tacchetti;Lucia... Pantani;Annamaria Brioli;Angela Flores Dico;Beatrice Anna Zannetti;Serena Rocchi;Michele Cavo | 2014-01-01 | EXPERIMENTAL CELL RESEARCH | - | 1.01 Articolo in rivista | - |
| Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. | Walker BA;Wardell CP;Melchor L;Brioli A;Johnson DC;Kaiser MF;Mirabella F;Lopez-Corral L;Humphray ...S;Murray L;Ross M;Bentley D;Gutiérrez NC;Garcia-Sanz R;San Miguel J;Davies FE;Gonzalez D;Morgan GJ | 2014-01-01 | LEUKEMIA | - | 1.01 Articolo in rivista | - |
| Maintenance therapy in newly diagnosed multiple myeloma: current recommendations. | Brioli, A; Tacchetti, P; Zamagni, E; Cavo, M | 2014-01-01 | EXPERT REVIEW OF ANTICANCER THERAPY | - | 1.01 Articolo in rivista | - |
| Peripheral neuropathy induced by subcutaneous bortezomib-based induction therapy for newly diagnosed multiple myeloma. | Brioli, A; Zannetti, Ba; Zamagni, E; Tacchetti, P; Pantani, L; Mancuso, K; Pezzi, A; Rocchi, Sere...na; Cavo, M | 2014-01-01 | HAEMATOLOGICA | - | 1.01 Articolo in rivista | 099e242.pdf |
| Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome. | Brioli A;Giles H;Pawlyn C;Campbell JP;Kaiser MF;Melchor L;Jackson GH;Gregory WM;Owen RG;Child JA;...Davies FE;Cavo M;Drayson MT;Morgan GJ | 2014-01-01 | BLOOD | - | 1.01 Articolo in rivista | - |
| Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma. | Melchor L;Brioli A;Wardell CP;Murison A;Potter NE;Kaiser MF;Fryer RA;Johnson DC;Begum DB;Hulkki W...ilson S;Vijayaraghavan G;Titley I;Cavo M;Davies FE;Walker BA;Morgan GJ | 2014-01-01 | LEUKEMIA | - | 1.01 Articolo in rivista | - |
| The impact of intra-clonal heterogeneity on the treatment of multiple myeloma. | Brioli A;Melchor L;Cavo M;Morgan GJ | 2014-01-01 | BRITISH JOURNAL OF HAEMATOLOGY | - | 1.01 Articolo in rivista | - |
| The impact of long-term lenalidomide exposure on the cellular composition of bone marrow. | Brioli A;Melchor L;Titley I;Vijayaraghavan G;Stephens C;Zeisig A;Pawlyn C;Cavo M;Morilla R;Davies... FE;Morgan GJ | 2014-01-01 | LEUKEMIA & LYMPHOMA | - | 1.01 Articolo in rivista | - |
| The utility of newer imaging techniques as predictors of clinical outcomes in multiple myeloma. | Brioli, A; Morgan, Gj; Durie, B; Zamagni, E | 2014-01-01 | EXPERT REVIEW OF HEMATOLOGY | - | 1.01 Articolo in rivista | - |